LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study

Adjuvant immunotherapy is currently moving into earlier stages of melanoma. CPG7909, a Toll-like receptor-9 (TLR9) agonist, injected at the primary tumour excision site in patients with clinical stage I/II melanoma, was found to boost loco-regional and systemic anti-melanoma immunity. In an exploratory analysis this was accompanied by a significant decrease in tumour-positive sentinel lymph node (SLN) rates and improved recurrence-free survival (RFS). To confirm these results we performed a randomized, placebo-controlled and double-blind phase II study of TLR9 agonist IMO-2125 in stage II pT3-4/cN0 melanoma.